Shore, N. D., Crawford, E. D., Szmulewitz, R. Z., Petrylak, D., Holzbeierlein, J., Villers, A., … Armstrong, A. J. (2020). Impact of baseline disease volume and prior docetaxel therapy on PSA-related outcomes in patients with mHSPC receiving enzalutamide plus ADT. In SWISS MEDICAL WEEKLY (pp. 25S-26S).

Shore, N. D., E. D. Crawford, R. Z. Szmulewitz, D. Petrylak, J. Holzbeierlein, A. Villers, A. Azad, et al. “Impact of baseline disease volume and prior docetaxel therapy on PSA-related outcomes in patients with mHSPC receiving enzalutamide plus ADT.” In SWISS MEDICAL WEEKLY, 25S-26S, 2020.

Shore ND, Crawford ED, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, et al. Impact of baseline disease volume and prior docetaxel therapy on PSA-related outcomes in patients with mHSPC receiving enzalutamide plus ADT. In: SWISS MEDICAL WEEKLY. 2020. p. 25S-26S.

Shore, N. D., et al. “Impact of baseline disease volume and prior docetaxel therapy on PSA-related outcomes in patients with mHSPC receiving enzalutamide plus ADT.” SWISS MEDICAL WEEKLY, 2020, pp. 25S-26S.

Shore ND, Crawford ED, Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Baron B, Haas GP, Stenzl A, Armstrong AJ. Impact of baseline disease volume and prior docetaxel therapy on PSA-related outcomes in patients with mHSPC receiving enzalutamide plus ADT. SWISS MEDICAL WEEKLY. 2020. p. 25S-26S.